New drug treatments for alcohol problems: A critical appraisal

Addiction

Volumn 92, Issue 8, 1997, Pages 939-947

  Moncrieff, Joanna ^a   Drummond, D Colin ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BROMOCRIPTINE; BUSPIRONE; NALTREXONE; SEROTONIN UPTAKE INHIBITOR;

ALCOHOL CONSUMPTION; ALCOHOLISM; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; HUMAN; RELAPSE; REVIEW; SIDE EFFECT;

ALCOHOLISM; ANTI-ANXIETY AGENTS; BUSPIRONE; DOPAMINE ANTAGONISTS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TAURINE;

EID: 0030748437     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.1997.tb02966.x     Document Type: Review

References (47)

1. SINCLAIR, J. D., ADKINS, J. & WALKER, S. (1973) Morphine-induced suppression of voluntary alcohol drinking in rats, Nature, 246, 425-427.
2. VOLPICELLI, J. R., DAVIS, M. A. & OLGIN, J. E. (1986) Naltrexone blocks the post shock increase of ethanol consumption, Life Sciences, 38, 841-847.
3. NARANJO, C. A., KADLEC, K. E., SANHUEZA, P., WOODLEY-REMUS, D. V. & SELLERS, E. M. (1991) Enalapril effects on alcohol intake and other consummatory in alcoholics, Clinical Pharmacology and Therapeutics, 50, 96-106.
4. SCHMIDT, L. G., DUFEU, P., KUHN, S. & ROMMELSPACHER, H. (1994) Relapse prevention in alcoholics with an anticraving drug treatment: first results of the Berlin study, Pharmacopsychiatry, 27(suppl 1), 21-23.
5. SHAW, G. K., MAJUMDAR, S. K., WALLER S., MACGARVIE, J. & DUNN, G. (1987) Tiapride in the long-term management of alcoholics of anxious or depressive temperament, British Journal of Psychiatry, 150, 164-168.
6. DRUMMOND, D. C., COOPER, T. & GLAUTIER, S. P. (1990) Conditioned learning in alcohol dependence: implications for cue exposure treatment, British Journal of Addiction, 85, 725-743.
7. SCHULTZ, K. F., CHALMERS, I., HAYES, R. J., & ALTMAN, D. G. (1995) Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, Journal of the American Medical Association, 273, 408-412.
8. TONEATTO, T., SELLERS, E. M., SOBELL, L. C. & SOBELL, M. B. (1992) Perception of whether drug or placebo has been administered is a determinant of drinking reduction, in: NARANJO, C. A., & SELLERS, E. M. (Eds) Novel Pharmacological Interventions for Alcoholism, pp. 161-183 (New York, Springer Verlag).
9. MARINI, J. L., SHEARD, M. H., BRIDGES, C. I., & WAGNER, E. J. (1976) An evaluation of the double-blind design in a study comparing lithium carbonate with placebo, Acta Psychiatrica Scandinavica, 53, 343-354.
10. WHITE, K., KANDO, J., PARK, T., WATERNAUX, C. & BROWN, W. A. (1992) Side effects and the "blindability" of clinical drug trials, American Journal of Psychiatry, 149, 1730-1761.
11. MAY, G. S., DEMETS, D. L., FREIDMAN, L. M., FURBERG, C., & PASSAMANI, E. (1981) The randomised clinical trial: bias in analysis, Circulation, 4, 942-951.
12. LEE, Y. J., ELLENBERG, J. H., HIRTZ, D. G., & NELSON, K. B. (1991) Analysis of clinical trials by treatment actually received: is it really an option? Statistics in Medicine, 10, 1595-1605.
13. LEJOYEUX, M. & ADES, J. (1993) Evaluation of lithium treatment in alcoholism, Alcohol and Alcoholism, 28, 273-279.
14. LITTLETON, J. (1995) Acamprosate in alcohol dependence: how does it work? Addiction, 90, 1179-1188.
15. LHUINTRE, J. P., MOORE, N. D., SALIGAUT, C., et al. (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics, Lancet, 1, 1014-1016.
16. PELC, I., LE BON, O., VERBANCK, P., LEHERT, P., & OPSOMER, L. (1992) Calcium-acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo controlled double-blind multicenter study, in: NARANJO, C. A., (ed.) Novel Pharmacological Interventions in Alcoholism, pp. 348-352 (New York, Springer).
17. LADEWIG, D., KNECHT, T., LEHER, P., & FENDL, A. (1993) Acamprosat - ein Stabilisierungsfaktor in der langzeitentwohnung von alkoholabhangigen, Therapeutische Umschau, 50, 182-188.
18. LHUINTRE, J. P., TRAN, G., STERU, L., et al. (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics, Alcohol and Alcoholism, 25, 613-622.
19. PAILLE, F. M., GUELFI, J. D., PERKINS, A. C., ROYER, R. J., STERU, L. & PAROT, P. (1995) Double-blind randomised multicentre trial of acamprosate in maintaining abstinence from alcohol, Alcohol and Alcoholism, 30, 239-247.
20. WHITWORTH, A. B., FISCHER, F., LESCH, O. M., et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence, Lancet, 347, 1438-1442.
21. SASS, H., SOYKA, M., MANN, K., & ZIEGLGANSBERGER, W. (1996) Relapse prevention by acamprosate, Archives of General Psychiatry, 53, 673-680.
22. VOLPICELLI, J. R., WATSON, N. T., KING, A. C., SHERMAN, C. E., & O'BRIEN, C. P. (1995) Effect of naltrexone on alcohol "high" in alcoholics, American Journal of Psychiatry, 152, 613-615.
23. VOLPICELLI, J. R., CLAY, K. L., WATSON, N. T., & O'BRIEN, C. P. (1995) Naltrexone in the treatment of alcoholism: predicting the response to naltrexone, Journal of Clinical Psychiatry, 56, 39-44.
24. VOLPICELLI, J. R., ALTERMAN, A. I., HAYASHIDA, M., & O'BRIEN, C. P. (1992) Naltrexone in the treatment of alcohol dependence, Archives of General Psychiatry, 49, 876-880.
25. O'MALLEY, S. S., JAFFE, A. J., CHANG, G., SCHOTTENFELD, R. S., MEYER, R. E., & ROUNSAVILLE, B. (1992) Naltrexone and coping skills therapy for alcohol dependence, Archives of General Psychiatry, 49, 881-887.
26. CHICK, J. (1996) UK multicentre study of naltrexone as adjunctive therapy in the treatment of alcoholism: efficacy results, Abstracts of the Xth World Congress of Psychiatry, 1, 230.
27. KOOB, G. F. (1992) Drugs of abuse: anatomy, pharmacology and function of reward, Trends in Pharmacological Science, 13, 177-184.
28. DONGIER, M., VACHON, L., & SCHWARTZ, G. (1991) Bromocriptine in the treatment of alcohol dependence, Alcoholism: Clinical and Experimental Research, 15, 970-977.
29. 2 dopamine receptor allele, Nature Medicine, 1, 337-341.
30. BORG, V. (1983) Bromocriptine in the prevention of alcohol abuse, Acta Psychiatrica Scandinavica, 68, 100-110.
31. BALLENGER, J. C., GOODWIN, F. K., MAJOR, L. F. & BROWN, G. L. (1979) Alcohol and central serotonin metabolism in man, Archives of General Psychiatry, 36, 224-227.
32. NARANJO, C. A., SELLERS, E. M., ROACH, C. A., WOODLEY, D. V., SANCHEZ-CRAIG, M. & SYKORA, K. (1984) Zimeldine-induced variations in alcohol intake by nondepressed heavy drinkers, Clinical Pharmacology and Therapeutics, 35, 374-381.
33. NARANJO, C. A., SELLERS, E. M., SULLIVAN, J. T., KADLEC, K. E., & SYKORA, K. (1987) The serotonin uptake inhibitor citalopram attenuates ethanol intake, Clinical Pharmacology and Therapeutics, 41, 266-274.
34. NARANJO, C. A., SULLIVAN, J. T., KADLEC, K. E., WOODLEY-REMUS, D. V., KENNEDY, G. & SELLERS, E. M. (1989) Differential effects of viqualine on alcohol intake and other consummatory behaviors, Clinical Pharmacology and Therapeutics, 46, 301-309.
35. NARANJO, C. A., KADLEC, K. E., SANHUEZA, P., WOODLEY-REMUS, D. & SELLERS, E. M. (1990) Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers, Clinical Pharmacology and Therapeutics, 47, 490-498.
36. NARANJO, C. A., BREMNER, K. E., & LANCTOT, K. L. (1995) Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems, Addiction, 90, 87-99.
37. 2 antagonist in heavy social drinkers: desire to drink, alcohol intake and related effects, Addiction, 90, 893-905.
38. GORELICK, D. A. & PAREDES, A. (1992) Effect of fluoxetine on alcohol consumption in male alcoholics, Alcoholism: Clinical and Experimental Research, 16, 261-265.
39. KRANZLER, H. R., BURLESON, J. A., KORNER, P., et al. (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics, American Journal of Psychiatry, 152, 391-397.
40. TOLLEFSON, G. D. (1989) Serotonin and alcohol: interrelationships, Psychopathology, 22 (suppl. 1), 37-48.
41. BRUNO, F. (1989) Buspirone in the treatment of alcoholic patients, Psychopathology, 22(suppl.1), 49-59.
42. TOLLEFSON, G. D., LANCASTER, S. P. & MONTAGUE-CLOUSE, J. (1991) The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency, Psychopharmacology Bulletin, 27, 163-170.
43. MALCOLM, R., ANTON, R. F., RANDALL, C. L., JOHNSTON, A., BRADY, K. & THEVOS, A. (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics, Alcoholism: Clinical and Experimental Research, 16, 1007-1013.
44. KRANZLER, H. R., BURLESON, J. A., DEL BOCA, F. K., et al. (1994) Buspirone treatment of anxious alcoholics, Archives of General Psychiatry, 51, 720-731.
45. MARLATT, G. A., & GORDEN, J. R. (1985) Relapse Prevention: maintenance strategies in the treatment of addictive behaviours (New York, Guilford Press).
46. PEACHEY, J. E. & ANNIS, H. (1985) New strategies for using the alcohol sensitising drugs, in: NARANJO, C. A., & SELLERS, E. M., (eds) Recent Advances in New Psychopharmacological Treatments for Alcoholism, pp. 199-216 (New York, Excerpta Medica Amsterdam).
47. JELLINEK, E. M. (1960) The Disease Concept of Alcoholism (New Haven, Hillhouse Press).